



SPAFID  
CONNECT

Informazione Regolamentata n. 20106-2-2021	Data/Ora Ricezione 18 Gennaio 2021 17:56:28	MTA - Star
--	---	------------

Societa' : Pharmanutra S.p.A.  
Identificativo : 141484  
Informazione  
Regolamentata  
Nome utilizzatore : PHARMANUTRAN01 - Lacorte  
Tipologia : REGEM  
Data/Ora Ricezione : 18 Gennaio 2021 17:56:28  
Data/Ora Inizio : 18 Gennaio 2021 17:56:30  
Diffusione presunta  
Oggetto : PR PHN - new advisory body 18\_01\_2021

*Testo del comunicato*

Vedi allegato.

## PHARMANUTRA S.P.A. APPOINTS A SUPERVISORY BODY

Pisa, 18<sup>th</sup> January 2021 - PharmaNutra S.p.A. (the "**Company**") communicates that the Board of Directors' meeting today has appointed a Supervisory Body pursuant to Legislative Decree 231/2001.

The Supervisory Body of the Company, with members Ms Rosa Annarumma (external member as Chairman), Mr Guido Carugi (Statutory Auditor) and Mr Pasquale Giovinazzo (Head of Internal Audit), will remain in office until approval of the financial statements for fiscal year 2022.

### PharmaNutra S.p.A.

*Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The effectiveness of its products is documented by considerable scientific proof. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of approximately 130 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in 50 countries abroad, through 32 partners selected from among the finest pharmaceutical companies. Over the years, PharmaNutra has stood out in the production of iron-based nutritional supplements with the trademark SiderAL<sup>®</sup>, where it can claim important Sucrosomial Technology<sup>®</sup> patents. The Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.*

[PharmaNutra.it](http://PharmaNutra.it)

For information:

#### PharmaNutra S.p.A.

Via Delle Lenze, 216/b - 56122 Pisa

Tel. +39 050 7846500

[investorrelation@pharmanutra.it](mailto:investorrelation@pharmanutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

#### Press Office - Spriano Communication & Partners

Via Santa Radegonda, 16 - 20121 Milan

Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)

Fine Comunicato n.20106-2

Numero di Pagine: 3